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Introduction: Whether adiponectin levels associate with atherogenesis in RA is uncertain. We examined the
independent relationships of total and high molecular weight (HMW) adiponectin concentrations with
cardiometabolic risk and surrogate markers of enhanced early atherogenesis in black and white patients with RA.
Methods: We determined total and HMW adiponectin concentrations and those of endothelial activation
molecules including soluble E-selectin, vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion
molecule-1 (ICAM-1) and monocyte chemoattractant protein-1 (MCP-1), in 210 (119 black and 91 white) RA patients.
Associations were determined in potential confounder and mediator adjusted mixed regression models.
Results: Total and HMW adiponectin concentrations related similarly to metabolic risk factors and endothelial
activation. In all patients, total and HMW adiponectin concentrations associated paradoxically with high systolic,
diastolic and mean blood pressure (partial R = 0.155 to 0.241, P ≤0.03). Ethnic origin did not impact on these
relationships (interaction P ≥0.09). Total and HMW adiponectin concentrations associated with those of glucose in
white and black patients respectively (partial R = −0.304, P = 0.006 and −0.246, P = 0.01). In black but not white
participants, total and HMW adiponectin concentrations also related favorably to lipid profiles (partial R = 0.292 to
0.360, P ≤0.003 for HDL cholesterol concentrations, -0.269 to −0.299, P ≤0.006 for triglyceride concentrations
and −0.302 to −0.390, P ≤0.002 for total-HDL cholesterol ratio) and the number of metabolic risk factors (partial
R = −0.210 to −0.238, P ≤0.03). In white but not black patients, total and HMW adiponectin concentrations
associated paradoxically with overall endothelial activation as estimated by a standard z-score of endothelial
activation molecule concentrations (partial R = 0.262, P = 0.01 and 0.252, P = 0.02); in the respective models, the
extent of effect of total and HMW adiponectin concentrations on endothelial activation was larger in white
compared to black participants (standardized β (SE) = 0.260 (0.107) versus −0.106 (0.107), P = 0.01 and 0.260 (0.120)
versus −0.100 (0.111), P = 0.02). The HMW-total adiponectin ratio related inconsistently to metabolic risk factors and
not to endothelial activation.
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Conclusion: In this study, total and HMW adiponectin concentrations associated with increased blood pressure
parameters, and in white patients additionally with endothelial activation. The potential mechanism(s) underlying
these paradoxical relationships between adiponectin concentrations and cardiovascular risk in RA merit further
investigation.Introduction
Human adiponectin was identified in 1999 as the most
abundant gene product in white adipose tissue [1]. Cir-
culating concentrations of this adipokine are reduced in
obesity [1,2]. Adiponectin decreases free fatty acid pro-
duction and enhances insulin sensitivity [3] and its cir-
culating concentrations associate with reduced plasma
glucose and serum triglyceride levels and increased high
density lipoprotein cholesterol concentrations, decreased
blood pressure and a lower risk of type 2 diabetes
[2,4-8]. These effects of adiponectin would be expected
to translate into reduced cardiovascular disease risk. Be-
sides, adiponectin additionally improves vascular health
directly by mechanisms that include reduced endothelial
activation through inhibition of nuclear factor κB activa-
tion dependent endothelial adhesion molecule produc-
tion [9] as well as the synthesis of endothelial monocyte
chemoattractant protein-1 [10], a crucial molecule in
early atherogenesis [11]. However, although an initial
study revealed a reduced risk of myocardial infarction in
relation to high adiponectin concentrations [12], a
subsequent large prospective investigation and meta-
analysis by Sattar and colleagues as reported in 2006,
found no association with coronary heart disease risk
[13]. Moreover, subsequent studies reported paradoxical
positive relationships between adiponectin concentra-
tions and cardiovascular disease risk in elderly subjects
[14,15], patients with heart failure [14] or prevalent
cardiovascular disease [16] and black Americans [17].
While among the different isoforms of adiponectin, it is
particularly high molecular weight (HMW) adiponectin
that confers the potential antidiabetic [18] and vascular
protective activities [19] of adiponectin in the general
population, a potential association with incident coro-
nary heart disease was also not confirmed [20].
Adiponectin further modulates inflammatory and im-
mune responses and was shown to be involved in the
pathogenesis of rheumatoid arthritis (RA) [21-23]. In-
deed, adiponectin induces gene expression and protein
synthesis of many pro-inflammatory and pro-destructive
molecules in several effector cells that participate in the
pathophysiology of RA [24-27].
Our knowledge on the association of adiponectin
levels with cardiovascular disease in RA is currently
more limited [28-34]. Notably in this context, the pres-
ence of autoimmunity can alter the relationship betweenadipokines and cardiovascular disease risk [35-37]. Thus,
Hahn and colleagues found that leptin administration
enhanced pro-inflammatory high density lipoprotein
scores as well as atherosclerosis in lupus prone but not
non-immune mice [35]. Leptin concentrations also asso-
ciated with cardiovascular risk in patients with lupus
[36]. In addition, we recently documented that RA im-
pacts on the relationships of total adiponectin concen-
trations with both lipid profiles and blood pressure
among black Africans with RA [37]. Nevertheless, it re-
mains unknown whether this finding represents either
an ethnicity or disease specific effect among patients
with RA. Importantly in the present context, genetic de-
terminants of adiponectin levels [38] and adiponectin-
cardiovascular disease relations in the general population
differ by ethnic grouping [17,39].
In the present investigation, we examined the impact
of population grouping on independent total and HMW
adiponectin concentration-metabolic cardiovascular risk
factor relationships and whether adiponectin levels
associate with surrogate markers of enhanced early
atherogenesis including soluble E-selectin, vascular
cell adhesion molecule-1 (VCAM-1), intercellular ad-
hesion molecule-1 (ICAM-1) and monocyte chemo-




The present investigation was conducted according to
the principles outlined in the Helsinki declaration.
The Committee for Research on Human Subjects of the
University of Witwatersrand approved the protocol
(approval number: M06-07-33 in RA subjects). Partici-
pants gave informed, written consent. The study design
was previously described [48-51]. Briefly, 210 African pa-
tients (119 black and 91 white) that met the 1987
American College of Rheumatology and 2010 American
College of Rheumatology/European League Against
Rheumatism criteria for RA [52,53] were enrolled at the
Charlotte Maxeke Johannesburg Academic Hospital and
Milpark Hospital [48-51]. All invited participants agreed
to participate. Data were missing in fewer than 5% of
any of the recorded characteristics.
Data on previously diagnosed established cardiovascu-
lar disease were derived by hospital record review.
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We recorded demographic features and smoking status.
Height, weight and waist and hip circumference were
measured using standard approaches. The body mass
index (BMI) was calculated and abdominal obesity and
fat distribution were estimated by waist circumference
and waist-hip ratio, respectively [48]. We recorded dis-
ease duration and rheumatoid factor status. Disease ac-
tivity was assessed by the Disease Activity Score in 28
joints (DAS28) [54]. C-reactive protein concentrations
were determined using immunoturbidimetric methods.
Standard laboratory blood tests of renal and liver func-
tion, hematological parameters, lipids and glucose were
performed. The glomerular filtration rate was estimated
using the Modification of Diet in Renal Disease equation
[55]. Cardiovascular drugs included antihypertensive
agents and glucose and lipid lowering drugs.
Among metabolic risk factors, hypertension was de-
fined as an average systolic blood pressure ≥140 or/and
diastolic blood pressure ≥90 mmHg or/and current use
of antihypertensive medications. Dyslipidemia was diag-
nosed when the atherogenic index, that is, the choles-
terol:high density lipoprotein (HDL) cholesterol ratio
was >4 and proatherogenic non-HDL cholesterol con-
centrations were calculated by subtracting HDL choles-
terol from total cholesterol concentrations [48-51,56-59].
Diabetes was identified as the use of glucose lowering
agents or a fasting plasma glucose ≥7 mmol/l. We calcu-
lated the number of metabolic risk factors using the Na-
tional Cholesterol Education Program defined metabolic
syndrome (MetS) definitions for MetS blood pressure,
HDL cholesterol, triglycerides and glucose [60].
We measured endothelial activation molecule concen-
trations including those of soluble E-selectin, VCAM-1,
ICAM-1 and MCP-1 using a solid-phase sandwich en-
zyme linked immunosorbant assay (Quantikine®HS, R &
D Systems, Inc., Minneapolis, MN, USA). Their lower
detection limits were 0.009 ng/l, 0.6 ng/l, 0.096 ng/l and
5.0 pg/ml, respectively; their inter- and intra-assay coef-
ficients of variation were 7.9 and 5.8, 7.0 and 3.1, 5.5
and 4.6 and 5.7 and 5.8, respectively.
Total and HMW adiponectin concentrations were
measured using solid-phase sandwich enzyme-linked im-
munosorbant assays (ELISA) (Quantikine®HS, R&D Sys-
tems, Inc.). Their lower detection limits were 0.246 and
0.195 ng/ml respectively. The inter- and intra-assay
coefficients of variation were 6.5 and 3.5% for total
and 8.5 and 3.0% for high molecular weight adipo-
nectin, respectively.
Data management and analysis
Dichotomous variables are expressed as proportions or
percentages and continuous variables as mean (SD), or me-
dian (interquartile range) when non-normally distributed.Non-normally distributed characteristics were also loga-
rithmically transformed prior to their inclusion in multi-
variable statistical analysis. An endothelial activation score
was employed to provide a summary measure of endothe-
lial activation and was calculated from SD (z) scores
as follows: [z (selectin) + z (VCAM-1) + z (ICAM-1) + z
(MCP-1)] [61].
Disparities in baseline characteristics, cardiovascular
drug use, metabolic risk factors, endothelial activation
molecule concentrations and adiponectin variables bet-
ween African black and white patients with RA were as-
sessed using the Student’s t-test, Mann–Whitney U test
and univariate logistic regression analysis as appropriate.
The associations of age, sex and population grouping
with adiponectin variables were assessed by entering the
respective characteristics together in single mixed re-
gression models. Associations of other baseline cha-
racteristics with adiponectin variables were evaluated
in models with adjustment for all three demographic
characteristics.
The independent relations of adiponectin variables
with metabolic risk factors and early endothelial activa-
tion were assessed in demographic characteristic, glom-
erular filtration rate and waist circumference (potential
confounders or/and determinants identified in previous
analysis) and cardiovascular drug use adjusted mixed
linear regression models. The impact of population
grouping on the relations of adiponectin variables with
metabolic risk factors and endothelial activation was as-
sessed by adding an interaction term (population grou-
ping (white = 1; black = 2) x adiponectin variable) to the
models, and in stratified analysis, that is, in black and
white participants separately.
Statistical computations were made using the GB Stat™
program (Dynamic Microsystems, Inc, Silver Spring,
MD, USA) and SAS software, version 9.1 (The SAS
Institute, Cary, NC, USA).
Results
Baseline characteristics, cardiovascular drug use,
metabolic risk factors, endothelial activation and
adiponectin variables in African black and white patients
with RA
Table 1 shows that as compared to their white counter-
parts, black patients were more often women, smoked
less frequently, had a higher BMI but lower waist-hip ra-
tio, higher DAS28, C-reactive protein concentrations
and glomerular filtration rate and used more conventio-
nal disease-modifying antirheumatic drugs (DMARDs)
but no biologic agents; they experienced more prevalent
hypertension, higher blood pressure values and dif-
ferences in some of the recorded individual lipid var-
iables but not in their cholesterol-HDL cholesterol and
triglycerides-HDL cholesterol ratios, and used lipid
Table 1 Baseline characteristics, cardiovascular drug use, metabolic risk factors, surrogate markers of enhanced early
atherogenesis and adiponectin variables in African black and white patients with rheumatoid arthritis
Characteristics Black (n = 119) White (n = 91) P
Baseline characteristic
Age, years 55.8 (10.2) 58.6 (10.9) 0.06
Female (%) 89.1 76.7 0.02
Smoking 3.4 11.1 0.04
Body mass index, kg/m2 29.3 (6.6) 25.7 (4.7) <0.0001
Waist circumference, cm 93.3 (13.4) 90.2 (12.7) 0.08
Waist-hip ratio 0.85 (0.80 to 0.90) 0.87 (0.82 to 0.93) 0.03
RA duration, years 12.8 (9.2) 14.1 (9.3) 0.3
Rheumatoid factor positive (%) 77.3 76.4 0.8
DAS28 4.2 (1.3) 3.6 (1.6) 0.007
C-reactive protein, mg/ml 7.0 (4.0 to 14.5) 4.1 (1.9 to 11.8) 0.007
Glomerular filtration rate, ml/min/1.73 m2
Conventional disease modifying agents use
105 (1) 89 (1) 0.0001
Any (%) 100 100 1.0
Number 2.5 (1.0) 2.2 (0.09) 0.02
Methotrexate (%) 90.8 79.1 0.02
Chloroquine (%) 79.8 55.0 0.0002
Leflunomide (%) 20.2 38.5 0.004
Sulphasalazine (%) 24.1 12.1 0.03
Azathioprine (%) 16.8 11.0 0.2
Tetracycline (%) 10.1 13.2 0.5
Cyclophosphamide (%) 5.9 1.1 0.1
Penicillamine (%) 4.2 2.2 0.4
Tumor necrosis-α inhibitor (%) 0.0 8.8 …
Rituximab (%) 0.0 1.5 …
Prednisone (%) 1.7 3.3 0.5
Cardiovascular drug use
Antihypertensive agents (%) 54.6 44.4 0.2
Oral glucose lowering agents (%) 13.5 4.4 0.04
Insulin (%) 0.8 2.2 0.4
Statin (%) 19.4 38.9 0.002
Ezetimibe (%) 0.0 2.2 …
Metabolic risk factors
Hypertension (%) 72.3 49.5 0.0008
Systolic blood pressure, mmHG 140 (25) 130 (17) 0.0004
Diastolic blood pressure, mmHG 86 (15) 80 (9) 0.0005
Mean blood pressure, mmHg 104 (17) 113 (13) 0.0002
Cholesterol-HDL cholesterol ration >4 (%) 21.7 14.8 0.2
Total cholesterol, mmol/l 4.7 (0.9) 5.1 (1.1) 0.004
HDL cholesterol, mmol/l 1.5 (1.3 to 1.8) 1.6 (1.3 to 2.0) 0.07
Cholesterol-HDL cholesterol ratio 3.2 (1.1) 3.2 (1.0) 0.80
LDL cholesterol, mmol/l 2.6 (0.8) 2.8 (0.9) 0.03
Non HDL cholesterol, mmol/l 3.1 (0.9) 3.4 (1.0) 0.05
Triglycerides, mmol/l 1.0 (0.7 to 1.3) 1.0 (0.9 to 1.4) 0.4
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Table 1 Baseline characteristics, cardiovascular drug use, metabolic risk factors, surrogate markers of enhanced early
atherogenesis and adiponectin variables in African black and white patients with rheumatoid arthritis (Continued)
Triglycerides-HDL cholesterol ratio 0.67 (0.46 to 1.10) 0.64 (0.46 to 0.93) 0.6
Diabetes (%) 16.0 7.8 0.08
Glucose, mmol/l 4.9 (4.5 to 5.4) 4.7 (4.4 to 5.1) 0.1
Metabolic risk factors, number* 1.4 (0.9) 1.0 (0.8) 0.005
Endothelial activation
E-selectin, ng/ml 42.23 (19.78) 36.05 (17.20) 0.02
VCAM-1, ng/ml 841.84 (696.33 to 1071.75) 791.01 (641.33 to 1033.44) 0.3
ICAM-1, ng/ml 238.10 (170.92 to 314.52) 309.19 (256.51 to 384.74) <0.0001
MCP-1, pg/ml 349.31 (224.75 to 665.07) 460.12 (329.71 to 681.86) 0.01
Endothelial activation score −0.25 (2.35) 0.32 (2.35) 0.09
Adiponectin variables
Total adiponectin, ng/ml 7.41 (4.62 to 11.56) 7.25 (5.31 to 12.83) 0.4
HMW adiponectin, ng/ml 2.65 (1.54 to 5.53) 3.82 (2.10 to 6.00) 0.05
HMW-total adiponectin ratio 0.44 (0.20) 0.50 (0.27) 0.07
Results are expressed as mean (SD) or median (interquartile range) unless indicated otherwise. Significant disparities are shown in bold. *Includes MetS defined
reduced high density lipoprotein cholesterol and elevated triglycerides, blood pressure and glucose criteria. DAS28, Disease activity score in 28 joints; HDL, High-
density lipoprotein; HMW, High molecular weight; ICAM, Intercellular adhesion molecule; LDL, Low-density lipoprotein; MCP, Monocyte chemoattractant protein;
RA, Rheumatoid arthritis; VCAM, Vascular cell adhesion molecule.
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drugs more frequently. The number of metabolic risk
factors was larger in black compared with white patients.
E-selectin concentrations were higher and those of
ICAM-1 and MCP-1 lower in black compared to white
participants; black patients had lower HMW adiponectin
concentrations and, consequently, their HMW-total adi-
ponectin ratio was numerically lower.
Total and high molecular weight adiponectin concen-
trations were highly correlated in all, black and white pa-
tients (R = 0.617 (P <0.0001), R = 0.801 (P <0.0001) and
R = 0.478 (P <0.0001), respectively).
Only seven patients had previously diagnosed estab-
lished cardiovascular disease that included one myocar-
dial infarction (white), five cerebrovascular accidents
(four white and one black) and one peripheral vascular
disease (white).
Associations between baseline recorded characteristics
and adiponectin variables in patients with RA
As given in Table 2, in confounder adjusted analysis, age
associated with HMW adiponectin concentrations, female
gender with those of both total and HMW adiponectin
concentrations and black ethnicity with low HMW-total
adiponectin ratios. Among the anthropometric measures,
BMI and, to a larger extent, waist circumference associ-
ated with low total and HMW adiponectin concentrations.
An inverse relationship between glomerular filtration rate
and total adiponectin concentrations approached signifi-
cance. In contrast to the findings in a recently reportedinvestigation [34] that was performed among early un-
treated patients with RA, disease activity was unrelated to
adiponectin concentrations in those with treated estab-
lished disease. Smoking status was not associated with
adiponectin concentrations and also not related to endo-
thelial activation (data not shown).
In separate models in which age, sex, glomerular fil-
tration rate, cardiovascular drug use and waist circum-
ference were adjusted for, black ethnicity was not related
to both total and HMW adiponectin concentrations
(P = 0.9 for both) but associated with low HMW-total
adiponectin concentration ratios (P = 0.05). Further ad-
justment for hypertension, diabetes and established car-
diovascular disease did not alter these results (P = 0.9,
0.9 and 0.06 for black ethnicity-total and HMW adi-
ponectin concentrations and -HMW-total adiponectin
ratio relations respectively). These results were also simi-
lar in separate models in which age, sex, waist circum-
ference, glomerular filtration rate and the number of
metabolic risk factors (see Table 1) were entered as po-
tential confounders or mediators (P = 0.7, 0.5 and 0.06
for black ethnicity-total and high molecular adiponectin
concentrations and -HMW-total adiponectin ratio rela-
tions, respectively).
Independent relations of adiponectin variables with
metabolic risk factors and surrogate markers of enhanced
early atherogenesis in patients with RA
Tables 3 and 4 show the demographic characteristic,
glomerular filtration rate, cardiovascular drug use and
Table 2 Associations between baseline characteristics and total* and high-molecular weight adiponectin
concentrations* and high molecular weight-total adiponectin ratios in patients with rheumatoid arthritis
Total HMW HMW-total
Adiponectin Adiponectin Adiponectin
Characteristic Partial R P Partial R P Partial R P
Age 0.082 0.2 0.154 0.02 0.115 0.09
Female 0.163 0.01 0.160 0.02 0.080 0.2
Black ethnicity −0.088 0.2 −0.036 0.6 −0.137 0.04
Smoking −0.090 0.7 −0.009 0.9 −0.055 0.4
Body mass index* −0.167 0.01 −0.136 0.05 0.037 0.6
Waist circumference −0.217 0.001 −0.219 0.001 −0.052 0.4
Waist-hip ratio* −0.074 0.3 −0.115 0.1 −0.092 0.1
RA duration 0.019 0.7 −0.010 0.9 −0.032 0.6
RF positive −0.024 0.7 −0.023 0.7 −0.017 0.8
DAS28 −0.077 0.3 0.043 0.5 0.081 0.3
C-reactive protein* −0.083 0.2 0.018 0.8 0.068 0.3
GFR −0.119 0.09 0.024 0.7 0.087 0.2
Associations were determined in demographic characteristic adjusted mixed linear regression models. Significant disparities are shown in bold. *Log transformed;
DAS28, Disease activity score in 28 joints; GFR, Glomerular filtration rate; RA, Rheumatoid arthritis; RF, Rheumatoid factor.
Table 3 Independent relations of total adiponectin concentrations* with cardiometabolic risk and surrogate markers of
enhanced early atherogenesis in African black and white patients with rheumatoid arthritis
Patients
Interaction All (n = 210) Black (n = 119) White (n = 91)
Characteristic Partial R P Partial R P Partial R P Partial R P
Metabolic risk factor
Systolic blood pressure 0.039 0.6 0.232 0.001 0.304 0.001 0.157 0.1
Diastolic blood pressure −0.032 0.7 0.203 0.004 0.248 0.01 0.200 0.07
Mean blood pressure 0.026 0.7 0.241 0.008 0.298 0.002 0.181 0.1
Total cholesterol −0.139 0.06 −0.164 0.02 −0.138 0.1 −0.213 0.06
HDL cholesterol* 0.201 0.005 0.126 0.08 0.360 0.002 −0.170 0.1
Total-HDL cholesterol ratio −0.270 0.0002 −0.231 0.001 −0.390 <0.0001 −0.027 0.9
LDL cholesterol −0.131 0.07 −0.158 0.03 −0.178 0.08 −0.142 0.2
Non-HDL cholesterol −0.244 0.0007 −0.209 0.004 −0.292 0.003 −0.132 0.2
Triglycerides* −0.204 0.005 −0.231 0.003 −0.299 0.002 −0.060 0.5
Triglycerides-HDL cholesterol ratio* −0.254 0.0004 −0.221 0.002 −0.379 <0.0001 0.045 0.7
Glucose* −0.104 0.1 −0.126 0.08 −0.109 0.3 −0.304 0.006
Number of metabolic risk factors −0.244 0.0007 −0.120 0.1 −0.238 0.01 0.047 0.6
Early atherogenesis
Selectin −0.068 0.3 −0.040 0.6 −0.062 0.5 −0.029 0.7
VCAM-1* −0.165 0.02 0.122 0.09 −0.020 0.8 0.262 0.01
ICAM-1* −0.109 0.1 0.012 0.9 −0.083 0.4 0.147 0.1
MCP-1* −0.122 0.09 0.100 0.2 −0.001 1.0 0.297 0.006
Endothelial activation score −0.203 0.005 0.080 0.3 −0.071 0.4 0.262 0.01
Relationships were determined in demographic characteristic, log glomerular filtration, cardiovascular drug use and waist circumference adjusted models.
Significant associations are shown in bold. *Log transformed. HDL, High density lipoprotein; ICAM, Intercellular adhesion molecule; LDL, Low density lipoprotein;
MCP, Monocyte chemoattractant protein; VCAM, Vascular cell adhesion molecule.
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Table 4 Independent relations of high molecular weight adiponectin concentrations* with cardiometabolic risk and
surrogate markers of enhanced early atherogenesis in African black and white patients with rheumatoid arthritis
Patients
Interaction All (n = 210) Black (n = 119) White (n = 91)
Characteristic Partial R P Partial R P Partial R P Partial R P
Metabolic risk factor
Systolic blood pressure 0.122 0.09 0.217 0.002 0.304 0.001 0.123 0.1
Diastolic blood pressure 0.022 0.7 0.155 0.03 0.257 0.01 0.143 0.2
Mean blood pressure 0.107 0.1 0.216 0.002 0.298 0.002 0.143 0.2
Total cholesterol −0.149 0.04 −0.002 1.0 −0.095 0.3 0.074 0.5
HDL cholesterol* 0.214 0.003 0.214 0.003 0.292 0.003 0.180 0.1
Total-HDL cholesterol ratio −0.190 0.009 −0.196 0.006 −0.302 0.002 −0.112 0.3
LDL cholesterol −0.119 0.1 −0.036 0.6 −0.121 0.2 0.018 0.8
Non-HDL cholesterol −0.190 0.009 −0.094 0.1 −0.221 0.03 −0.002 1.0
Triglycerides* −0.212 0.009 −0.137 0.05 −0.269 0.006 −0.003 0.9
Triglycerides-HDL cholesterol ratio* −0.211 0.003 −0.202 0.004 −0.329 0.0008 0.094 0.4
Glucose* −0.215 0.003 −0.155 0.03 −0.246 0.01 −0.143 0.2
Number of metabolic risk factors −0.193 0.007 −0.155 0.03 −0.210 0.03 −0.148 0.2
Early atherogenesis
Selectin −0.044 0.5 −0.013 0.9 −0.051 0.6 −0.019 0.8
VCAM-1* −0.079 0.2 0.128 0.08 −0.007 0.9 0.240 0.03
ICAM-1* −0.129 0.08 0.103 0.1 −0.007 0.9 0.286 0.009
MCP-1* −0.054 0.4 0.021 0.8 −0.011 0.9 0.153 0.1
Endothelial activation score −0.123 0.07 0.098 0.1 −0.058 0.5 0.252 0.02
Relationships were determined in demographic characteristic, log glomerular filtration, cardiovascular drug use and waist circumference adjusted models.
Significant associations are shown in bold. *Log transformed. HDL, High density lipoprotein; ICAM, Intercellular adhesion molecule; LDL, low density lipoprotein;
MCP, Monocyte chemoattractant protein; VCAM, Vascular cell adhesion molecule.
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variables with metabolic risk factors and endothelial
activation molecules in all patients. As given in Table 3,
in all patients, total adiponectin concentrations were
independently related to high systolic, diastolic and
mean blood pressure and low total, low density lipo-
protein (LDL) and non-HDL cholesterol and triglyce-
ride concentrations, and low total-HDL cholesterol and
triglycerides-HDL cholesterol ratios. Population group-
ing impacted on the total adiponectin-HDL cholesterol
concentration, -total-HDL cholesterol ratio, -non-HDL
cholesterol and -triglyceride concentration and trigly-
ceride-HDL cholesterol ratio, -number of metabolic risk
factors and -VCAM-1 concentration and -endothelial
activation score relations. In stratified analysis, total
adiponectin concentrations associated significantly with
high blood pressure values as well favorable lipid param-
eters and low number of metabolic risk factors in black
but not white patients; total adiponectin concentrations
related to low glucose concentrations and large VCAM-
1 and MCP-1 concentrations as well as large endothelial
activation score in white but not black participants.As shown in Table 4, in all patients, HMW adi-
ponectin concentrations were independently related to
high systolic, diastolic and mean blood pressure and
large HDL cholesterol concentrations, low total HDL
cholesterol ratios and triglyceride concentrations, tri-
glycerides-HDL cholesterol ratios, glucose concentra-
tions and number of metabolic risk factors. Population
grouping impacted on the HMW adiponectin-total chol-
esterol and -HDL cholesterol ratio, non-HDL cholesterol
and triglyceride concentration, total-HDL cholesterol
and triglycerides-HDL cholesterol ratio, glucose concen-
tration and number of metabolic risk factors relations.
In stratified analysis, HMW adiponectin concentrations
associated significantly with high blood pressure values
as well as favorable lipid parameters, low glucose con-
centrations and low number of metabolic risk factors in
black but not white patients; HMW adiponectin concen-
trations related to large VCAM-1 and ICAM-1-1 con-
centrations as well as large endothelial activation score
in white but not black participants.
As given in Additional file 1: Table S1, in all patients,
HMW-total adiponectin ratio associated with high total
Table 6 Relations of total and high- molecular weight
adiponectin concentrations with surrogate markers of
enhanced early atherogenesis after further adjustment
for the number of metabolic risk factors* and smoking in
white patients with rheumatoid arthritis








Endothelial activation score 0.221 0.04
Significant associations are shown in bold. *Metabolic risk factors that were
forced into the models included MetS defined reduced high density
lipoprotein cholesterol and elevated triglycerides, blood pressure and glucose.
†Log transformed. ICAM, Intercellular adhesion molecule; MCP, Monocyte
chemoattractant protein; VCAM, Vascular cell adhesion molecule.
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ted on the HMW-total adiponectin ratio-total, LDL,
non-HDL cholesterol and glucose concentration rela-
tions. In stratified analysis, HMW-total adiponectin ratio
associated with low glucose concentrations in black but
not white patients, and with large LDL-cholesterol con-
centrations in white but not back participants.
Because population grouping did not impact on total
and HMW adiponectin-blood pressure relations but the
respective associations were not significant in white pa-
tients in stratified analysis (Tables 3 and 4), we further
compared the extent of effect of total and HMW adi-
ponectin on blood pressure parameters between black
and white patients, in the respective models. As shown
in Table 5, the extent of effect of total and HMW
adiponectin on blood pressure parameters was similar in
black compared with white patients.
By contrast and also as given in Table 5, except for the
HMW-VCAM-1 relation (P = 0.09), the extent of effect
of total and HMW adiponectin on surrogate markers of
enhanced early atherogenesis in the respective models
(Tables 2, 3 and 4) was larger in white compared to
black patients.
Table 6 shows that the relations of total and HMW
adiponectin concentrations with surrogate markers of
enhanced early atherogenesis in white participants
(Tables 3 and 4), is independent of not only potentialTable 5 Comparison of extent of effect of total and high
molecular weight adiponectin concentrations on blood
pressure and surrogate markers of enhanced early
atherogenesis between black and white patients with
rheumatoid arthritis, in mixed regression models
Standardized β (SE)
Black (n = 119) White (n = 91) P
Total adiponectin* versus
Systolic blood pressure 0.321 (0.099) 0.146 (0.103) 0.2
Diastolic blood pressure 0.257 (0.099) 0.176 (0.096) 0.5
Mean blood pressure 0.309 (0.098) 0.166 (0.101) 0.3
VCAM-1* −0.028 (0.109) 0.276 (0.110) 0.05
MCP-1* −0.029 (0.112) 0.293 (0.105) 0.03
Endothelial activation score −0.106 (0.107) 0.260 (0.107) 0.01
HMW adiponectin* versus
Systolic blood pressure 0.341 (0.101) 0.119 (0.107) 0.1
Diastolic blood pressure 0.207 (0.103) 0.148 (0.101) 0.6
Mean blood pressure 0.308 (0.089) 0.137 (0.106) 0.2
VCAM-1* −0.015 (0.112) 0.257 (0.116) 0.09
ICAM-1* −0.086 (0.118) 0.292 (0.109) 0.02
Endothelial activation score −0.100 (0.111) 0.260 (0.120) 0.02
Significant associations are shown in bold. *Log transformed. ICAM,
Intercellular adhesion molecule; MCP, Monocyte chemoattractant protein;
VCAM, Vascular cell adhesion molecule.confounders and/or determinants as identified in the
present analysis (Table 2) but also of metabolic risk fac-
tors including the MetS defined HDL, triglycerides,
blood pressure and glucose criteria [60] as well as smo-
king. Additional adjustment for C-reactive protein con-
centrations did also not materially alter these results
(data not shown).
Finally, our findings on total and HMW adiponectin-
blood pressure relations (Tables 3 and 4) were materially
unaltered upon further adjustment for potentially con-
founding RA characteristics comprising disease duration
(cumulative inflammation), DAS28, C-reactive protein
concentrations, rheumatoid factor status (disease severity)
and the employed number of conventional DMARDs
and biologic agent and prednisone use [62-65] (data
not shown).
Discussion
In the present study, total and HMW adiponectin con-
centrations related to a similar extent to metabolic risk
factors in RA, as was previously documented in the non-
RA population [20]. We found two similarities and three
disparities in adiponectin-cardiovascular risk relations in
black compared to white patients with RA. The former
comprised positive adiponectin-blood pressure variable
and inverse adiponectin-glucose concentration associa-
tions, and the latter positive adiponectin-favorable lipid
profile and overall number of metabolic risk factors rela-
tionships in black but not white patients as well as posi-
tive adiponectin-endothelial activation associations in
white but not black participants.
Numerous experimental studies have documented the
protective effects of adiponectin on obesity induced
pathological conditions, including insulin resistance and
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tivity enhancing effect would be expected to reduce high
blood pressure, direct effects of adiponectin on compo-
nents of vascular tissue are considered more important
in this context [66]. These comprise the activating ef-
fects of adiponectin on endothelial nitric oxide (NO)
synthase and cyclooxygenase-2 leading to the production
of NO and prostaglandin-I2 production, respectively,
and the ability of adiponectin to promote macrophage
polarization toward the anti-inflammatory phenotype,
which results in reduced interleukin-6, tumor necrosis
factor (TNF)-α and MCP-1 and increased arginase-1,
interleukin-1 and macrophage N-acetyl-galactosamine
specific lectin-1 by M1 and M2 macrophages, respect-
ively [66]. Each of these processes improves endothelial
function.
Patients with RA experience substantially increased
risk for cardiovascular disease [67-72]. Over the recent
past, paradoxical positive relations between adiponectin
concentrations and cardiovascular risk were reported in
non-RA populations at high risk of cardiovascular dis-
ease [14-17]. In this context, we recently also found for
the first time a paradoxical positive association between
total adiponectin concentrations and blood pressure pa-
rameters in African black RA but not non-RA subjects
[37]. In the present investigation we assessed total and
HMW adiponectin concentrations and comprehensively
adjusted for potential mediating and confounding char-
acteristics in our analysis. Our current finding of positive
relations between both total and HMW adiponectin
concentrations and each of three blood pressure vari-
ables that were further present to a statistically similar
extent in black and white patients argues against our
previous result [37] being spurious and supports the
notion that these relationships may be RA specific. Add-
itionally, we found paradoxical positive associations be-
tween total and HMW adiponectin concentrations and
endothelial activation in white patients only and indeed,
in the respective models, the extent of effect of adi-
ponectin concentrations on surrogate markers of en-
hanced early atherogenesis was significantly larger in
white compared to black study participants. Thus, this
relationship was ethnic specific among patients with RA.
Importantly in this regard, not only do genetic loci as-
sociated with adiponectin levels differ in black compared
with whites but also, in the Health ABC study, adi-
ponectin concentrations associated independently with
prevalent and incident coronary heart disease in black
but not white non-RA Americans [17]. Taken together,
the impact of ethnicity on the adiponectin-cardio-
vascular risk relation may be reversed in subjects with
RA. Further, whereas white ethnicity associates with
higher adiponectin concentrations among black and
white non-RA Americans and this association is drivenby visceral adiposity and metabolic risk factors [17,39],
ethnicity was not related to adiponectin levels both be-
fore and after adjustment for waist circumference and
metabolic risk factors in the present RA cohort. Congru-
ent with our previous findings [37], our current results
suggest that findings on adiponectin metabolism and its
associations with cardiovascular risk as reported in the
non-RA population should not be merely translated to
the RA population.
Potential mechanisms underlying the reported para-
doxical adiponectin-cardiovascular risk relations were
recently comprehensively and elegantly proposed by
Sattar [73]. Among six raised possibilities, an attractive
option was that of reverse causality, whereby increased
adiponectin concentrations represent a chronic or acute
on chronic compensatory mechanism to counteract
metabolic and vascular stress in subjects with acute
coronary syndrome or heart failure [73]. Recommenda-
tions for investigations aimed at elucidating paradoxical
adiponectin-cardiovascular risk relations were also given.
Total and HMW adiponectin concentrations were
strongly interrelated in the present RA investigation but
the HMW-total adiponectin ratio was inconsistently as-
sociated with metabolic risk factors. The HMW-total
adiponectin ratio was also not related to endothelial
activation.
The previously alluded to paradoxical relation between
total adiponectin and coronary heart disease among
non-RA black Americans was postulated to result from
a decreased production of HMW relative to other adi-
ponectin isoforms in this population group [17,39]. We
indeed found that HMW adiponectin concentrations
were lower in black compared to white patients and
black ethnicity associated with a lower HMW-total adi-
ponectin ratio in age and sex adjusted analysis. However,
HMW adiponectin concentrations were also shown to
be unrelated to incident coronary heart disease [20].
RA adipocytes and their surrounding macrophages
produce adipokines that regulate systemic inflammation
and the presence of a complex adipokine-mediated
interaction among white adipose tissue, cardiovascular
disease and chronic inflammatory disease like RA was
previously proposed [74]. In this regard, in a series of
white patients with severe RA undergoing anti-TNF-α
infliximab therapy, high grade inflammation showed an
independent negative correlation with circulating adipo-
nectin concentrations whereas low adiponectin levels
clustered with metabolic syndrome features including
dyslipidemia and high plasma glucose concentrations
that reportedly contribute to atherogenesis in RA [75].
However, adiponectin concentrations were not related to
blood pressure in this study. In another series of non-
diabetic and mostly non-obese patients with ankylosing
spondylitis undergoing anti-TNF-α therapy, adiponectin
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to low BMI [76]. Taken together, these findings support a
role of hypoadiponectinemia in cardiometabolic risk in
chronic inflammatory rheumatic diseases. The present
study shows that in RA, ethnicity and presumably genetic
factors may modulate metabolic risk through mechanisms
that include an effect mediated by adipokines.
Our study has strengths and limitations. We assessed
both total and HMW adiponectin concentrations and
the production of four endothelial activation molecules,
which reportedly mediates the initial stages of athero-
sclerosis [40-43] and is inhibited by adiponectin [9-11].
Endothelial activation is markedly enhanced and associ-
ated with disease characteristics that further are strongly
implicated in increased cardiovascular risk, and hence
constitutes a promising tool in the elucidation of athe-
rogenic mechanisms in RA [44-47]. Importantly, endo-
thelial activation was not associated with disease activity
variables in the present cohort of patients with estab-
lished and treated RA [61]. The cross sectional design of
the present investigation precludes drawing inferences
on the direction of causality and our results need to be
reproduced in a longitudinal study, preferably with the
inclusion of cardiovascular event rates as an outcome
variable. Alcohol intake and physical activity can associ-
ate with increased adiponectin concentrations [6]. Only
15.3% of patients in the present study consumed alcohol
with a median of three units per week, alcohol con-
sumption was not related to total and HMW adipo-
nectin concentrations (P = 0.4 and 0.5) and its inclusion
as an additional confounder in the models in Tables 3, 4,
5 and 6 did not alter our findings (data not shown). The
same lack of relationships was also present with regard
to physical activity [36] (data not shown). Finally, the
relative role of genetic [38] versus environmental factors,
including socioeconomic characteristics [6] in the ethni-
city-adiponectin and adiponectin-cardiovascular risk re-
lationships among patients of different population origin
in RA, were not determined and merit further study.
Conclusions
In this study, adiponectin concentrations related inversely
to those of glucose, and in black patients to favorable lipid
profiles. These relationships are similar to those reported
in the non-RA population. However, adiponectin concen-
trations also independently associated with increased
blood pressure parameters, and in white patients additio-
nally with enhanced endothelial activation. The possible
mechanism(s) underlying these paradoxical relationships
together with the concurrent presence of beneficial associ-
ations merit further investigation in order to determine
the potential role of adiponectin in cardiovascular disease
as well as its concentrations in cardiovascular disease risk
stratification in RA.Additional file
Additional file 1: Table S1. Independent relations of high molecular
weight-total adiponectin ratio with cardiometabolic risk and surrogate
markers of enhanced early atherogenesis in African black and white
patients with rheumatoid arthritis.
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